Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 6:13:1227657.
doi: 10.3389/fonc.2023.1227657. eCollection 2023.

Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges

Patrycja Aleksandra Bukłaho  1   2 , Joanna Kiśluk  1 , Jacek Nikliński  1
Affiliations
Review

Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges

Patrycja Aleksandra Bukłaho et al. Front Oncol. .

Abstract

Due to predictions of increasing incidences and deaths from ovarian cancer, this neoplasm is a challenge for modern health care. The advent of NGS technology has made it possible to understand the molecular characteristics of many cancers, including ovarian cancer. The data obtained in research became the basis for the development of molecularly targeted therapies thus leading to the entry of NGS analysis into the diagnostic process of oncological patients. This review presents targeted therapies currently in preclinical or clinical trials, whose promising results offer hope for their use in clinical practice in the future. As more therapeutic options emerge, it will be necessary to modify molecular diagnostic regimens to select the best treatment for a given patient. New biomarkers are needed to predict the success of planned therapy. An important aspect of public health is molecular testing in women with a familial predisposition to ovarian cancer enabling patients to be included in prevention programs. NGS technology, despite its high throughput, poses many challenges, from the quality of the diagnostic material used for testing to the interpretation of results and classification of sequence variants. The article highlights the role of molecular testing in ongoing research and also its role in the diagnostic and therapeutic process in the era of personalized medicine. The spread of genetic testing in high-risk groups, the introduction of more targeted therapies and also the possibility of agnostic therapies could significantly improve the health situation for many women worldwide.

Keywords: HBOC (hereditary breast and ovarian cancer); HGSOC; cancer precision medicine; cancer screening; ovarian cancer; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Targeted treatment options for HGSOC approved by the FDA and under study described in the text.
Figure 2
Figure 2
Possibilities of using NGS technology in the diagnostic and therapeutic process of ovarian cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Khanlarkhani N, Azizi E, Amidi F, Khodarahmian M, Salehi E, Pazhohan A, et al. . Metabolic risk factors of ovarian cancer: a review. JBRA Assisted Reprod (2022) 26(2):335–47. doi: 10.5935/1518-0557.20210067 - DOI - PMC - PubMed
    1. Huang J, Chan WC, Ngai CH, Lok V, Zhang L, Lucero-Prisno DE, III, et al. . Worldwide burden, risk factors, and temporal trends of ovarian cancer: A global study. Cancers (2022) 14:2230. doi: 10.3390/cancers14092230 - DOI - PMC - PubMed
    1. Otsuka I. Mechanisms of high-grade serous carcinogenesis in the fallopian tube and ovary: current hypotheses, etiologic factors, and molecular alterations. Int J Mol Sci (2021) 22:4409. doi: 10.3390/ijms22094409 - DOI - PMC - PubMed
    1. Bellcross CA. Hereditary breast and ovarian cancer. An updated primer for OB/GYNs. Obstet Gynecol Clin N Am (2022) 49:117–47. doi: 10.1016/j.ogc.2021.11.005 - DOI - PubMed
    1. Serio PAdMP, de Lima Pereira GF, Katayama MLH, Roela RA, Maistro S, Folgueira MAAK. Somatic mutational profile of high-grade serous ovarian carcinoma and triple-negative breast carcinoma in young and elderly patients: similarities and divergences. Cells (2021) 10:3585. doi: 10.3390/cells10123586 - DOI - PMC - PubMed